Finance

Lists
CSPCY:OTCMKTS
CSPC Pharmaceuticals Group ADR
US$4,81
+1,05%
(+0,050) 1D
28 ກ.ຍ., 16 ໂມງ 0 ນາທີ 00 ວິນາທີ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CSPCY...
Open
US$4,81
High
US$4,81
Low
US$4,81
Mkt. cap
109,81 ຕື້
Avg. vol.
1,28 ພັນ
Volume
540,00
52-wk high
US$5,46
52-wk low
US$3,26
Beta
0,40
Shares outstanding
2,88 ຕື້
No. of employees
19 ພັນ
Open
US$4,81
High
US$4,81
Low
US$4,81
Mkt. cap
109,81 ຕື້
Avg. vol.
1,28 ພັນ
Volume
540,00
52-wk high
US$5,46
52-wk low
US$3,26
Beta
0,40
Shares outstanding
2,88 ຕື້
No. of employees
19 ພັນ
News stories
From web sources and news partners
TipRanks
TipRanks
·
17 ຊົ່ວໂມງກ່ອນ
CSPC Wins China Trial Nod for Novel mRNA Cancer Vaccine SYS6077
Profile
CSPC Pharmaceutical Group researches, develops, manufactures and sells pharmaceutical products. Its headquarters is in China's Hebei Province. CSPC produces both active pharmaceutical ingredient and formulations. API products include penicillin, cefalosporins, synthetic vitamins, caffeine and ranitidine. Formulations include antibiotics, butylphthalide and analgesics, in addition to nearly 1,000 other products. CSPC's 15,000 employees are divided among more than ten subsidiaries, including CSPC Zhongrun, Weisheng, Zhongnuo and NBP. CSPC Pharma's total assets are valued above RMB 8 billion. In 2007, CSPC Pharma achieved sales of RMB 8 billion and net income of RMB 485 million. Direct exports of US$300 million ranked CSPC first among China's pharmaceutical enterprises. One subsidiary, China Pharmaceutical Group Co., Ltd is based in Hong Kong. It is listed on the Hang Seng China-Affiliated Corporations Index. In 2003 and 2004, China Pharma was listed as one of 100 excellent listed companies with turnover less than $1 billion. CSPC Pharma is recognized as one of China's "500 Most Valuable Chinese Brands" and "Top 500 Chinese Enterprises." Wikipedia
About CSPC Pharmaceuticals Group ADR
CEOZhang Cuilong
Employees18,6 ພັນ
Founded1992
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in HKD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
6,62 ຕື້
6,11 ຕື້
6,47 ຕື້
12,13 ຕື້
Cost of goods sold
2,28 ຕື້
2,11 ຕື້
2,20 ຕື້
2,24 ຕື້
Cost of revenue
2,28 ຕື້
2,11 ຕື້
2,20 ຕື້
2,24 ຕື້
Research and development expenses
1,50 ຕື້
1,62 ຕື້
1,40 ຕື້
1,63 ຕື້
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,97 ຕື້
1,87 ຕື້
1,89 ຕື້
1,89 ຕື້
Operating expense
3,47 ຕື້
3,49 ຕື້
3,29 ຕື້
3,51 ຕື້
Total operating expenses
5,75 ຕື້
5,60 ຕື້
5,49 ຕື້
5,75 ຕື້
Operating income
869,63 ລ້ານ
514,71 ລ້ານ
973,82 ລ້ານ
6,38 ຕື້
Other non operating income
645,49 ລ້ານ
-470,42 ລ້ານ
181,80 ລ້ານ
11,92 ລ້ານ
EBT including unusual items
1,18 ຕື້
505,59 ລ້ານ
1,13 ຕື້
6,40 ຕື້
EBT excluding unusual items
1,37 ຕື້
186,56 ລ້ານ
1,13 ຕື້
6,35 ຕື້
Income tax expense
222,47 ລ້ານ
165,64 ລ້ານ
243,25 ລ້ານ
825,70 ລ້ານ
Effective tax rate
18,78%
32,76%
21,46%
12,91%
Other operating expenses
-
-
-
-
Net income
963,54 ລ້ານ
370,72 ລ້ານ
859,79 ລ້ານ
5,23 ຕື້
Net profit margin
14,56%
6,06%
13,30%
43,16%
Earnings per share
-
-
-
-
Interest and investment income
-
195,87 ລ້ານ
-
91,68 ລ້ານ
Interest expense
-105,19 ລ້ານ
-6,76 ລ້ານ
-11,01 ລ້ານ
-2,30 ລ້ານ
Net interest expenses
-105,19 ລ້ານ
189,12 ລ້ານ
-11,01 ລ້ານ
89,37 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
1,14 ຕື້
802,06 ລ້ານ
1,26 ຕື້
6,67 ຕື້
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
ແອັບຂອງ Google